The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 6.57 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.29 — no flag raisedOK
- Earnings quality 90/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as BIO-RAD LABORATORIES, INC. reports it. History and quarterly detail are in the app.
- Clinical Diagnostics$1.6B
- Life Science$1.0B
Leadership changes
From BIO-RAD LABORATORIES, INC.'s own filings, the day they're filed.
- Rajat Mehta · Directors · departureeff. 2025-07-23
- James J. Barry · President · appointmenteff. 2024-05-01
- Andrew Last · Chief Operating Officer · departureeff. 2024-04-10
Latest filings
- 8-K · Company announcement2026-04-30
- 10-Q · Quarterly report2026-04-30
- 8-K · Company announcement2026-04-24
- DEF 14A · Annual proxy (pay & governance)2026-03-25
- 8-K · Company announcement2026-02-19
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about BIO-RAD LABORATORIES, INC., every answer cited🔒
- The Intelligence Brief — added when BIO-RAD LABORATORIES, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.